Fairfield Bush & CO. Has $1.05 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Fairfield Bush & CO. trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,839 shares of the life sciences company’s stock after selling 198 shares during the quarter. Fairfield Bush & CO.’s holdings in Illumina were worth $1,048,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in ILMN. Versant Capital Management Inc increased its position in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 146 shares in the last quarter. Golden State Wealth Management LLC acquired a new position in Illumina in the 4th quarter worth $32,000. Assetmark Inc. increased its holdings in Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after purchasing an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Illumina in the 4th quarter valued at about $45,000. Finally, Lee Danner & Bass Inc. bought a new stake in shares of Illumina in the fourth quarter valued at about $48,000. Institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of recent research reports. HSBC lowered Illumina from a “buy” rating to a “hold” rating and set a $100.00 target price on the stock. in a research report on Friday, February 28th. Robert W. Baird reduced their target price on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. Hsbc Global Res lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. Citigroup cut their price target on shares of Illumina from $90.00 to $85.00 and set a “neutral” rating on the stock in a research report on Monday, April 7th. Finally, Royal Bank of Canada lowered their target price on Illumina from $128.00 to $112.00 and set an “outperform” rating on the stock in a research report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Illumina currently has a consensus rating of “Moderate Buy” and a consensus target price of $138.70.

Illumina Stock Down 1.4 %

Illumina stock opened at $73.53 on Thursday. The company’s 50-day moving average price is $85.87 and its two-hundred day moving average price is $121.21. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The stock has a market cap of $11.65 billion, a P/E ratio of -9.57, a P/E/G ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.